STOCK TITAN

Stock Market News for November 16, 2026

848 stories published on Monday, November 16, 2026.

The day runs on New York time, and each time in the list shows the time zone it is in.

Daily news digest for

AI-generated digest, written by Rhea-AI from the day’s company announcements; each item links to its story. How Rhea-AI works. Not financial advice.

At a glance

On November 16, 2026, CG Oncology reported its Phase 3 PIVOT-006 trial reduced recurrence risk by 68% in intermediate-risk/high-grade Ta NMIBC; Rapid Micro Biosystems agreed to be acquired by Merck KGaA for $0.75 per share; Powell Industries posted Q4 revenue of $397 million and net income of $82 million.

Earnings and guidance

Powell Industries (POWL) announces fourth quarter and full year fiscal 2026 results with fourth-quarter revenue of $397 million, net income of $82 million, diluted EPS of $2.23, new orders of $710 million and backlog of $2.7 billion.

Aecom (ACM) reports fourth quarter and full year fiscal 2026 results with quarterly revenue of $3,878 million, diluted EPS from continuing operations of $0.99, adjusted EPS of $1.63 and record backlog of $28,016 million.

XCF Global (SAFX) reports third quarter 2026 financial results & affirms 2027 outlook with third-quarter revenue of $21.7 million and reaffirmed 2027 outlook of $650–$700 million gross product revenue and $70–$75 million adjusted EBITDA (ex-proposed acquisition).

AMC Robotics (AMCI) reports third quarter 2026 financial results with revenue of $0.97 million, gross margin 54.6% and net loss of $2.02 million as supply-chain relocation costs weighed on results.

Drug trials and approvals

CG Oncology (CGON) announces PIVOT-006 Phase 3 trial demonstrates improvement in RFS reporting cretostimogene reduced recurrence risk by 68% (hazard ratio 0.32; 95% CI 0.23–0.45; p<0.0001) with median follow-up 17 months and no Grade 3+ treatment-related AEs.

Helus Pharma (HELP) announces positive topline results from Phase 3 APPROACH study where HLP003 produced a Week 6 MADRS placebo-adjusted reduction of 7.6 points (19.5 vs. 11.9; p<0.0001) and improved response/remission rates.

Aclaris Therapeutics (ACRS) announces top line Phase 2 results for bosakitug (ATI-045) in atopic dermatitis reporting the ADMIRATION trial missed primary and secondary endpoints despite evidence of TSLP target engagement; bosakitug was generally well tolerated.

Cerenome (CNSY) reports interim ReSPECT-LM data supporting repeat dosing of REYOBIQ™ from 10 patients with no dose-limiting toxicities or discontinuations and no LM progression at three or six months among evaluable patients.

IN8bio (INAB) reports updated glioblastoma data at SNO 2026 showing median overall survival of 20.9 months and two-year survival of 50% in repeat-dose gamma-delta T cell–treated patients (data as of Oct. 30, 2026).

Deals and acquisitions

Rapid Micro Biosystems (RPID) signs definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany in an all-cash transaction at $0.75 per share, expected to close in December 2026 subject to tender and customary conditions.

Valor Energy (VAI) closes acquisition of an 18MW computing center in Youngstown, Ohio acquiring Glorious Star as a wholly owned subsidiary to convert the site into an AI data center.

Financings, offerings and listings

Windward Bio Group (WWB) lists on Nasdaq, shares up 68% on debut after an IPO priced at $17.00 per share selling ~10.29 million ordinary shares and raising gross proceeds of $225 million, including a $50 million private placement from Sanofi.

Corporate actions and programs

SunPower (SPWR) announces reverse stock split to implement a 1-for-35 reverse split effective 4:01 p.m. ET on Nov. 17, 2026, with split-adjusted trading beginning Nov. 18, 2026, to regain Nasdaq minimum bid-price compliance.

Other notable news

Xtend AI Robotics (XTND) reports third quarter 2026 results with Q3 revenue of $14.9 million, up 281% year over year, and a quarterly net loss of $44.6 million; cash totaled $66.7 million at Sep. 30.

Lexeo Therapeutics (LXEO) announces positive interim Phase I/II data and regulatory update for LX2020 reporting an 80% mean reduction in non-sustained ventricular tachycardia in high-dose participants and FDA openness to a surrogate primary endpoint.

Sun, Nov 15 Tue, Nov 17
IMPACT
SENTIMENT
IMPACT
SENTIMENT
dividends
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
penny stock
IMPACT
SENTIMENT
low float penny stock
IMPACT
SENTIMENT
low float penny stock
IMPACT
SENTIMENT
low float penny stock
IMPACT
SENTIMENT
IMPACT
SENTIMENT
penny stock
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
low float penny stock
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
AI low float penny stock
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
low float high short
IMPACT
SENTIMENT
low float penny stock
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
earnings low float high short
IMPACT
SENTIMENT
earnings low float penny stock
IMPACT
SENTIMENT
IMPACT
SENTIMENT
dividends low float
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
earnings low float penny stock
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
low float penny stock
IMPACT
SENTIMENT
dividends low float
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
private placement penny stock
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
low float penny stock
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
penny stock
IMPACT
SENTIMENT
partnership low float penny stock
IMPACT
SENTIMENT
IMPACT
SENTIMENT
management penny stock
IMPACT
SENTIMENT
earnings penny stock
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
private placement penny stock
IMPACT
SENTIMENT
IMPACT
SENTIMENT
dividends low float penny stock
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
private placement penny stock
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
IMPACT
SENTIMENT
Sun, Nov 15 Tue, Nov 17

You can use the feed to follow a portfolio or watchlist, research a company, or catch up on developments around shares you own.

It keeps the day's company news in one place, with the dated archive available when you need an earlier session.

What this page covers